Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Lipkowitz Website

Stanley Lipkowitz, M.D., Ph.D.

Selected Publications

1)  Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S.
Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
Cancer Res. 59: 734-41, 1999.
2)  Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y.
Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1.
Mol. Cell. 4: 1029-40, 1999.
3)  Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, Mariathasan S, Bouchard D, Wakeham A, Itie A, Le J, Ohashi PS, Sarosi I, Nishina H, Lipkowitz S, Penninger JM.
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b.
Nature. 403: 211-6, 2000.
4)  Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, Yarden Y, Weissman AM, Lipkowitz S.
Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex.
J Biol Chem. 276: 27677-84, 2001.
5)  Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, Lipkowitz S.
TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype.
Breast Cancer Res. Treat. 113: 217-230, 2009.
6)  Qiao G, Ying H, Zhao Y, Liang Y, Guo H, Shen H, Li Z, Solway J, Tao E, Chiang YJ, Lipkowitz S, Penninger JM, Langdon WY, Zhang J.
E3 ubiquitin ligase Cbl-b suppresses proallergic T cell development and allergic airway inflammation.
Cell Rep. 6: 709-23, 2014.
7)  Kales SC, Nau MM, Merchant AS, Lipkowitz S.
Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A.
PLoS ONE. 9: e87116, 2014.
8)  Garimella SV, Gehlhaus K, Dine JL, Pitt JJ, Grandin M, Chakka S, Nau MM, Caplen NJ, Lipkowitz S.
Identification of novel molecular regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.
Breast Cancer Res. 16: R41, 2014.
9)  Veselits M, Tanaka A, Lipkowitz S, O'Neill S, Sciammas R, Finnegan A, Zhang J, Clark MR.
Recruitment of Cbl-b to B cell antigen receptor couples antigen recognition to Toll-like receptor 9 activation in late endosomes.
PLoS ONE. 9: e89792, 2014.
10)  Wedam S, Lipkowitz S.
Yang S, Dancey J, eds.
HER-2 as a prognostic and predictive biomarker in cancer. In: Handbook of therapuetic biomarkers in cancer.
Singapore: Pan Stanford Publishing; 2013. p. 77-120 [Book Chapter]
11)  Ma K, Kales S, Lipkowitz S.
Yarden Y, Tarcic G, eds.
Cbl as a master regulator of RTK trafficking. In: Vesicle trafficking and cancer.
New York: Springer; 2013. p. 219-244 [Book Chapter]
12)  Kales SC, Ryan PE, Lipkowitz S.
Cbl exposes its RING finger.
Nat. Struct. Mol. Biol. 19: 131-3, 2012.
13)  Ryan PE, Kales SC, Yadavalli R, Nau MM, Zhang H, Lipkowitz S.
Cbl-c ubiquitin ligase activity is increased via the interaction of its RING finger domain with a LIM domain of the paxillin homolog, Hic 5.
PLoS ONE. 7: e49428, 2012.
14)  Guo H, Qiao G, Ying H, Li Z, Zhao Y, Liang Y, Yang L, Lipkowitz S, Penninger JM, Langdon WY, Zhang J.
E3 Ubiquitin Ligase Cbl-b Regulates Pten via Nedd4 in T Cells Independently of Its Ubiquitin Ligase Activity.
Cell Rep. 1: 472-482, 2012.
15)  Garimella SV, Rocca A, Lipkowitz S.
WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis.
Mol. Cancer Res. 10: 75-85, 2012.
16)  Yoon HY, Kales SC, Luo R, Lipkowitz S, Randazzo PA.
ARAP1 association with CIN85 affects epidermal growth factor receptor endocytic trafficking.
Biol. Cell. 103: 171-84, 2011.
17)  Lipkowitz S, Weissman AM.
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.
Nat. Rev. Cancer. 11: 629-43, 2011.
18)  Chavez KJ, Garimella SV, Lipkowitz S.
Triple Negative Breast Cancer Cell Lines: One Tool in the Search for Better Treatment of Triple Negative Breast Cancer.
Breast Dis. 32: 35-48, 2011.
19)  Kales SC, Ryan PE, Nau MM, Lipkowitz S.
Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.
Cancer Res. 70: 4789-94, 2010.
20)  Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K, Hasina R, Lo FY, El-Hashani E, Cervantes G, Robinson M, Kales SC, Lipkowitz S, Karrison T, Sattler M, Vokes EE, Wang YC, Salgia R.
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
PLoS ONE. 5: e8972, 2010.
21)  Murrow LM, Garimella SV, Jones TL, Caplen NJ, Lipkowitz S.
Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome.
Breast Cancer Res. Treat. 122: 347-57, 2010.
22)  Ryan PE, Sivadasan-Nair N, Nau MM, Nicholas S, Lipkowitz S.
The N-terminus of Cbl-c regulates ubiquitin ligase activity by modulating affinity for the ubiquitin conjugating enzyme.
J Biol Chem. 285: 23687-98, 2010.
23)  Lipkowitz S, Brinton L, Niederhuber J.
Bland K, Copeland E, eds.
Interval breast cancer: clinical, epidemiological, and biological features. In: The breast: comprehensive management of benign and malignant diseases.
Philadelphia: Saunder Elsevier; 2009. p. 657-666 [Book Chapter]
24)  Lipkowitz S.
Breast Dis. 15: 1-2, 2009.
25)  Stone B, Lipkowitz S.
Pumpfrage redivivus.
JAMA. 302: 626; author reply 626, 2009.
26)  Rahman M, Pumphrey JG, Lipkowitz S.
The TRAIL to targeted therapy of breast cancer.
Adv. Cancer Res. 103: 43-73, 2009.
27)  Nau M, Lipkowitz S.
Tsygankov A, eds.
The Cbl Family. In: Cbl Proteins.
New York: Nova Science Publishers, Inc; 2008. p. 3-25 [Book Chapter]
28)  Kato S, Sadarangani A, Lange S, Delpiano AM, Vargas M, Brañes J, Carvajal J, Lipkowitz S, Owen GI, Cuello MA.
2-methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts.
Reprod Sci. 15: 878-94, 2008.
29)  Lipkowitz S, Dennis PA.
PPARgamma Agonists Follow an Unknown TRAIL in Lung Cancer.
Cancer Biol Ther. 6, 2007.
30)  Peschard P, Kozlov G, Lin T, Mirza IA, Berghuis AM, Lipkowitz S, Park M, Gehring K.
Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b.
Mol. Cell. 27: 474-85, 2007.
31)  Sadarangani A, Kato S, Espinoza N, Lange S, Llados C, Espinosa M, Villalon M, Lipkowitz S, Cuello M, Owen GI.
TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract.
Apoptosis. 12: 73-85, 2007.
32)  Davies GC, Ryan PE, Rahman L, Zajac-Kaye M, Lipkowitz S.
EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins.
Oncogene. 25: 6497-509, 2006.
33)  Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R, Ma PC.
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
Nat Clin Pract Oncol. 3: 50-7, 2006.
34)  Cuello M, Kato S, Sadarangani A, Saez C, Gejman R, Owen G, Lipkowitz S.
Receptor mediated cell death: role of ovarian steroid hormones in TRAIL induced apoptosis in gynecologic cancers.
Bulletin of the School of Medicine of Chile. 31: 5-16, 2006.
35)  Ryan PE, Davies GC, Nau MM, Lipkowitz S.
Regulating the regulator: negative regulation of Cbl ubiquitin ligases.
Trends Biochem. Sci. 31: 79-88, 2006.
36)  Karlin JD, Nguyen D, Yang SX, Lipkowitz S.
Epidermal growth factor receptor expression in breast cancer.
J. Clin. Oncol. 23: 8118-9, 2005.
37)  Calzone KA, Prindiville SA, Jourkiv O, Jenkins J, DeCarvalho M, Wallerstedt DB, Liewehr DJ, Steinberg SM, Soballe PW, Lipkowitz S, Klein P, Kirsch IR.
Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer.
J Clin Oncol. 23: 3455-64, 2005.
38)  Zeng S, Xu Z, Lipkowitz S, Longley JB.
Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl).
Blood. 105: 226-32, 2005.
39)  Peschard P, Ishiyama N, Lin T, Lipkowitz S, Park M.
A conserved DpYR motif in the juxtamembrane domain of the met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.
J Biol Chem. 279: 29565-71, 2004.
40)  Davies GC, Ettenberg SA, Coats AO, Mussante M, Ravichandran S, Collins J, Nau MM, Lipkowitz S.
Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b.
Oncogene. 23: 7104-15, 2004.
41)  Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM.
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
J Clin Oncol. 22: 3080-90, 2004.
42)  Cuello M, Coats AO, Darko I, Ettenberg SA, Gardner GJ, Nau MM, Liu JR, Birrer MJ, Lipkowitz S.
N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines.
Cell Death Differ. 11: 527-41, 2004.
43)  Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, Kaye FJ, Zajac-Kaye M.
Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme.
Cancer Cell. 5: 341-51, 2004.
44)  Griffiths EK, Sanchez O, Mill P, Krawczyk C, Hojilla CV, Rubin E, Nau MM, Khokha R, Lipkowitz S, Hui CC, Penninger JM.
Cbl-3-deficient mice exhibit normal epithelial development.
Mol Cell Biol. 23: 7708-18, 2003.
45)  Nau MM, Lipkowitz S.
Comparative Genomic Organization of the Human cbl Genes.
Gene. 308: 103-113, 2003.
46)  Lipkowitz S.
The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer.
Breast Cancer Res. 5: 8-15, 2003.
47)  Magnifico A, Ettenberg S, Yang C, Mariano J, Tiwari S, Fang S, Lipkowitz S, Weissman AM.
WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation.
J Biol Chem. 278: 43169-43177, 2003.
48)  Cuello MA, Nau M, Lipkowitz S.
Apoptosis and the treatment of breast cancer.
Breast Dis. 15: 71-82, 2002.
49)  Szymkiewicz I, Kowanetz K, Soubeyran P, Dinarina A, Lipkowitz S, Dikic I.
CIN85 participates in Cbl-b-mediated down-regulation of receptor tyrosine kinases.
J Biol Chem. 277: 39666-72, 2002.
50)  Klein P, Glaser E, Grogan L, Keane M, Lipkowitz S, Soballe P, Brooks L, Jenkins J, Steinberg SM, DeMarini DM, Kirsch I.
Biomarker assays in nipple aspirate fluid.
Breast J. 7: 378-87, 2001.
51)  Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S.
Downregulation of the erbB-2 receptor by trastuzumab (Herceptin ) enhances TRAIL-mediated apoptosis in breast and ovarian cancer cell lines which overexpress erbB-2.
Cancer Res. 61: 4892-4900, 2001.
52)  Cuello M, Ettenberg SA, Nau MM, Lipkowitz S.
Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells.
Gynecol Oncol. 81: 380-390, 2001.
Click Here to View Collapsed Bibliography.

This page was last updated on 6/20/2014.